Article
Rheumatology
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L. Bhatt, Carol A. Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B. Shapiro, Janet E. Pope, Hendrik Schulze-Koops
Summary: This study aimed to characterize infections in patients with rheumatoid arthritis (RA) receiving different treatment regimens. The results showed that tofacitinib had a higher risk of infections compared to tumor necrosis factor inhibitors (TNFi). These findings may provide insights for future treatment decisions.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Jeffrey Weitz, Zoltan Szekanecz, Christina Charles-Schoeman, Ivana Vranic, Burak Sahin, Sara A. Paciga, Zhenyu Wang, Craig Hyde, David A. Martin
Summary: This exploratory post hoc analysis did not identify biomarkers that explained the increased VTE risk for tofacitinib versus TNFi. However, month 12 D-dimer levels were positively associated with risk of a subsequent VTE within the tofacitinib treatment arms.
Article
Rheumatology
Jeffrey R. Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L. Bhatt, Levent M. Gunay, Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J. Gomez-Reino
Summary: This study evaluated malignancies and their associations with baseline risk factors and cardiovascular risk scores in patients with rheumatoid arthritis (RA) treated with tofacitinib and tumour necrosis factor inhibitors (TNFi). The results showed that the risk of malignancies was increased with tofacitinib compared to TNFi, and the highest incidence was observed in patients with a history of atherosclerotic cardiovascular disease (HxASCVD) or increasing cardiovascular risk.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Pharmacology & Pharmacy
Ko-Jen Li, Chia-Li Chang, Chih-Yi Hsin, Chao-Hsiun Tang
Summary: This study found that TNFi were the preferred agents for RA treatment during 2012-2017. Non-TNFi and tofacitinib were common second-line agents being switched to. Nearly half of discontinued patients received retreatment, with a majority receiving the same agent.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Alessandro Conforti, Onorina Berardicurti, Viktoriya Pavlych, Ilenia Di Cola, Paola Cipriani, Piero Ruscitti
Summary: This study assessed the incidence and predictive factors of VTE in rheumatoid arthritis (RA) patients, finding older age, higher body mass index, and longer disease duration to be significant predictors of VTE occurrence. Further research is needed to provide more generalizable results to daily clinical practice.
Article
Biochemistry & Molecular Biology
Monika Czokolyova, Attila Hamar, Anita Pusztai, Gabor Tajti, Edit Vegh, Zsofia Petho, Nora Bodnar, Agnes Horvath, Boglarka Soos, Szilvia Szamosi, Anita Szentpeteri, Ildiko Seres, Mariann Harangi, Gyorgy Paragh, Gyorgy Kerekes, Levente Bodoki, Andrea Domjan, Katalin Hodosi, Tamas Seres, Gyorgy Panyi, Zoltan Szekanecz, Gabriella Szucs
Summary: The study found that tofacitinib treatment had balanced effects on lipids and other metabolic markers in patients with rheumatoid arthritis (RA). Various correlations were observed between lipids, clinical markers, and vascular pathophysiology in relation to tofacitinib treatment. Complex assessment of these factors could be used in clinical practice to monitor cardiovascular status and treatment response in RA patients.
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Rishi J. Desai, Ajinkya Pawar, Farzin Khosrow-Khavar, Michael E. Weinblatt, Seoyoung C. Kim
Summary: There was no significant difference in the risk of venous thromboembolism between patients with rheumatoid arthritis treated with tofacitinib and those treated with TNFα inhibitors.
Review
Pharmacology & Pharmacy
Mahta Mortezavi, Eduardo F. Mysler
Summary: We summarize the clinical efficacy and safety data of Tofacitinib from clinical trials, post hoc analyses, and real-world studies. These data provide evidence of the efficacy of Tofacitinib in treating RA patients at different stages and with various baseline characteristics. Safety data from different patient subpopulations are also reviewed, aiding in informed decision-making and individualized patient care.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2023)
Article
Rheumatology
Benedicte Delcoigne, Tine Iskov Kopp, Elizabeth Arkema, Karin Hellgren, Sella Aarrestad Provan, Heikki Relas, Kalle Aaltonen, Nina Trokovic, Bjorn Gudbjornsson, Gerdur Grondal, Eirik Klami Kristianslund, Jesper Lindhardsen, Lene Dreyer, Johan Askling
Summary: This study compared the incidences of neuroinflammatory events in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) starting a tumor necrosis factor inhibitor (TNFi). The results showed that the choice of specific TNFi did not seem to play an important role in the risk of neuroinflammatory events.
Article
Rheumatology
Alexander Platzer, Farideh Alasti, Josef S. Smolen, Daniel Aletaha, Helga Radner, Stephan Blueml
Summary: This study identified four distinct clusters of radiographic progression over a 2-year period in patients with rheumatoid arthritis (RA), including stable, relentless progression, improvement, and both ways, confirming the robustness of the clusters using different clustering methods. Regression models found disease duration, baseline C-reactive protein (CRP) and SHS, and treatment status as predictors for cluster assignment.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Public, Environmental & Occupational Health
Hong Ki Min, Hyeongsu Kim, Ho Jin Jeong, Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee, KunSei Lee, Soon-Ae Shin, Jong Heon Park
Summary: This study found that, compared to tumor necrosis factor inhibitors (TNFis), Janus kinase inhibitors (JAKis) did not increase the risk of acute myocardial infarction (AMI), stroke, cardiovascular (CV)-related mortality, major adverse cardiovascular events (MACE), venous thromboembolism (VTE), arterial thromboembolism (ATE), or cancer in Korean patients with rheumatoid arthritis (RA).
EPIDEMIOLOGY AND HEALTH
(2023)
Article
Rheumatology
Yusuf Karabulut, Halise Hande Gezer, Selin Esen, Irfan Esen, Ali Riza Turkoglu
Summary: This study aimed to explore the effects of tofacitinib on erectile dysfunction (ED), disease activity, and health-related quality of life in male patients with rheumatoid arthritis (RA). The results showed that tofacitinib monotherapy can improve the severity of ED, as well as disease activity and health-related quality of life in male RA patients with ED.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Yeo-Jin Song, Soo-Kyung Cho, Jeong-Yeon Kim, Seung-Hun You, Hyoungyoung Kim, Sun-Young Jung, Yoon-Kyoung Sung
Summary: This study compared the risk of venous thromboembolism (VTE) in Korean patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKis) or tumor necrosis factor (TNF) inhibitors, and found no increased risk of VTE in the JAKi treatment group compared to the TNF inhibitor treatment group.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Rheumatology
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
Summary: Based on primary results from ORAL Surveillance, this study identified two subpopulations of patients treated with tofacitinib who had different relative risks compared to TNFi. Older age and smoking were identified as risk factors associated with increased risk, while younger age and non-smoking were associated with no detectable risk increase. These findings have important implications for individualized treatment decisions with tofacitinib.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: The risk of serious infections associated with vedolizumab was found to be similar to anti-TNF in patients with inflammatory bowel disease (IBD) overall, but varied according to IBD subtype, with a decreased risk for patients with ulcerative colitis (UC) and no difference for patients with Crohn's disease (CD).
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Rheumatology
Chandrasekar Gopalakrishnan, Rishi J. Desai, Jessica M. Franklin, Yinzhu Jin, Joyce Lii, Daniel H. Solomon, Jeffrey N. Katz, Yvonne C. Lee, Patricia D. Franklin, Seoyoung C. Kim
Summary: This study aimed to develop a claims-based model for predicting persistent high-dose opioid use among patients who underwent total knee replacement (TKR). The study utilized Medicare claims data and employed group-based trajectory modeling to identify different patterns of opioid use. The findings revealed that approximately 10.6% of older patients became persistent high-dose opioid users after TKR.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Rheumatology
Rishi J. Desai, Ajinkya Pawar, Farzin Khosrow-Khavar, Michael E. Weinblatt, Seoyoung C. Kim
Summary: There was no significant difference in the risk of venous thromboembolism between patients with rheumatoid arthritis treated with tofacitinib and those treated with TNFα inhibitors.
Article
Public, Environmental & Occupational Health
Julie M. Paik, Elisabetta Patorno, Min Zhuo, Lily G. Bessette, Cassandra York, Nileesa Gautam, Dae Hyun Kim, Seoyoung C. Kim
Summary: Validation studies compared ICD-9 and ICD-10 codes with laboratory values to identify CKD Stages 3-5 patients, finding that a two-code algorithm combined with lab results within +/- 90 days achieved the highest PPV. ICD-10 codes showed comparable accuracy to ICD-9 codes, with all ICD-10 algorithms having PPVs >80%.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2022)
Article
Rheumatology
Sicong Huang, Tianrun Cai, Brittany N. Weber, Zeling He, Kumar P. Dahal, Chuan Hong, Jue Hou, Thany Seyok, Andrew Cagan, Marcelo F. DiCarli, Jacob Joseph, Seoyoung C. Kim, Daniel H. Solomon, Tianxi Cai, Katherine P. Liao
Summary: This study found that elevated inflammation early in the diagnosis of rheumatoid arthritis (RA) was associated with heart failure, specifically heart failure with preserved ejection fraction (HFpEF). The association was not observed with heart failure with reduced ejection fraction (HFrEF). This finding suggests a window of opportunity for prevention of HFpEF in RA patients.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Arnaud D. Kaze, Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno, Julie M. Paik
Summary: The study showed that the use of SGLT2i in patients with DKD is associated with reduced risks of MACE, kidney outcomes, HHF, and death. There is limited data on the associations between SGLT2i and safety outcomes, indicating the need for further research.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Pharmacology & Pharmacy
Andrei Barbulescu, Johan Askling, Saedis Saevarsdottir, Seoyoung C. Kim, Thomas Frisell
Summary: This study emulated a pragmatic trial using observational data and compared it with the results of a well-known trial. The findings showed that using a prespecified protocol in clinical registry data can replicate the results of the trial, favoring infliximab over SSZ + HCQ combination therapy at 9 months.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno, Julie M. Paik
Summary: This study aimed to investigate whether there is a difference in the risk of hospitalization for heart failure (HHF) between the initiation of sodium zirconium cyclosilicate (SZC) and patiromer for the treatment of hyperkalemia. The results from the matched analysis showed that the use of SZC was associated with a numerically higher risk of HHF compared to patiromer, but this difference did not reach statistical significance.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Rheumatology
Julie C. C. Lauffenburger, Zhigang Lu, Mufaddal Mahesri, Erin Kim, Angela Tong, Seoyoung C. C. Kim
Summary: This study used data-driven approach to classify and predict spending patterns in patients with gout. The study identified three distinct spending patterns: minimal spending, moderate spending, and high spending, and found that clinical predictors could help predict the spending groups. These findings are important for selecting appropriate interventions.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Public, Environmental & Occupational Health
Hemin Lee, Jeffrey A. Sparks, Su Been Lee, Kazuki Yoshida, Joan E. Landon, Seoyoung C. Kim
Summary: This study aims to determine the accuracy of ICD-10 diagnosis codes for rheumatoid arthritis (RA) serostatus using a US claims database (Optum Clinformatics Data Mart) and compare the results to a previous study. The results showed that the PPVs for seropositive and seronegative RA in the Optum database were lower than those in MarketScan, but improved when more restricted definitions of M05 and M06 were used.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Rheumatology
H. Lee, S. K. Chen, N. Gautam, S. M. Vine, M. He, R. J. Desai, M. E. Weinblatt, R. J. Glynn, S. C. Kim
Summary: The objective of this study was to investigate the incidence rate of skin cancer associated with methotrexate and hydroxychloroquine in older adults with rheumatoid arthritis (RA). The results showed that there was no significant difference in the risk of skin cancer between methotrexate and hydroxychloroquine users. However, methotrexate initiators had a higher risk of basal cell carcinoma (BCC) but a lower risk of squamous cell carcinoma (SCC) compared to hydroxychloroquine initiators.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Letter
Allergy
Lily Li, Joan E. Landon, Seoyoung C. Kim
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
(2022)
Article
Rheumatology
S. K. Tedeschi, Y. Jin, S. Vine, H. Lee, A. Pethoe-Schramm, V Yau, S. C. Kim
Summary: In these two U.S. GCA cohorts, high-dose glucocorticoids were the most common initial treatment. Over 25% of Medicare patients and 7% of MarketScan patients developed serious infections during follow-up. Older age and higher frailty score were associated with higher risk of serious infections.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Meeting Abstract
Critical Care Medicine
A. Pawar, M. S. Blaiss, B. D. Modena, A. H. Khan, L. De Prado Gomez, A. Nag, Y. Zhang, B. Ortiz, J. A. Jacob-Nara
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.